Daraxonrasib Pancreatic Cancer Pill nearly doubled survival in metastatic PDAC, beating second-line chemo with fewer discontinuations.
Daraxonrasib Pancreatic Cancer Pill Doubles Survival
Original Article by Andrew Gregory | The Guardian | 4 May 2026
Daraxonrasib Pancreatic Cancer Pill nearly doubled survival in metastatic PDAC, beating second-line chemo with fewer discontinuations.
More Posts
Acute Pain in African Hospitals Affects Two-Thirds of Patients
Acute pain in African hospitals affects two-thirds of patients – what the burden means for hospital groups and medical schemes.
Read more...
Mpox Cases in SA Rise as Local Transmission Accelerates
Mpox cases in South Africa are rising, mainly in the Western Cape. What the surge means for the healthcare industry.
Read more...
NHLS Scrambles as Pathology Services Funding Runs Dry
The NHLS is scrambling for new providers after funds for haematology pathology services ran dry, amid an R11.3bn provincial debt
Read more...